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NTHL1 biallelic mutations seldom 
cause colorectal cancer, serrated 
polyposis or a multi-tumor 
phenotype, in absence of colorectal 
adenomas
sami Belhadj  1,2, Isabel Quintana1,2, pilar Mur1,2,3, pau M. Munoz-torres1,2,  
M. Henar Alonso  2,4,5,6, Matilde Navarro1,2,3, Mariona terradas  1,2, Virginia piñol7,8, 
Joan Brunet  1,3,9, Victor Moreno  2,4,5,6, Conxi Lázaro1,2,3, Gabriel Capellá1,2,3 &  
Laura Valle  1,2,3
the cancer-predisposing syndrome caused by biallelic mutations in NTHL1 may not be a solely 
colorectal cancer (CRC) and polyposis syndrome but rather a multi-tumor recessive disease. the 
presence of ≤10 adenomas in several mutation carriers suggests a possible causal role of NTHL1 
in hereditary or early-onset nonpolyposis CRC. the involvement of NTHL1 in serrated/hyperplastic 
polyposis remains unexplored. the aim of our study is to elucidate the role of NTHL1 in the 
predisposition to personal or familial history of multiple tumor types, familial/early-onset nonpolyposis 
CRC, and serrated polyposis. NTHL1 mutational screening was performed in 312 cancer patients with 
personal or family history of multiple tumor types, 488 with hereditary nonpolyposis CRC, and 96 with 
serrated/hyperplastic polyposis. While no biallelic mutation carriers were identified in patients with 
personal and/or family history of multiple tumor types or with serrated polyposis, one was identified 
among the 488 nonpolyposis CRC patients. The carrier of c.268C>T (p.Q90*) and 550-1G>A was 
diagnosed with CRC and meningioma at ages 37 and 45 respectively, being reclassified as attenuated 
adenomatous polyposis after the cumulative detection of 26 adenomas. Our findings suggest that 
biallelic mutations in NTHL1 rarely cause CRC, a personal/familial multi-tumor history, or serrated 
polyposis, in absence of adenomas.
In 2015 Weren et al. described a hereditary cancer syndrome caused by biallelic mutations in the DNA base 
excision repair gene NTHL1, characterized by attenuated adenomatous polyposis and increased colorectal cancer 
(CRC) risk, largely resembling the recessive syndrome caused by MUTYH mutations1. To date, 33 homozygous 
or compound heterozygous NTHL1 mutation carriers have been reported (21 families)1–8. More than 5 colonic 
adenomas (range: 6 to >50) were identified in 24 of the 28 (85%) mutation carriers who underwent colonos-
copy screening, and CRC was diagnosed in 19 (68%) of them. Noteworthy, 17 carriers (57%) were diagnosed 
with multiple primary malignant tumors in extracolonic locations, being the most recurrently found breast and 
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endometrial tumors, head neck squamous cell carcimomas, meningiomas, and bladder and basal cell carcinomas, 
suggesting that the NTHL1-associated syndrome is a multi-tumor disease rather than a solely CRC syndrome. 
On the other hand, the fact that at least ¼ (7/28) of the reported biallelic mutation carriers who underwent 
colonoscopy screening had ≤10 adenomas, and that ≥5 hyperplastic polyps were detected in five carriers (polyp 
number range: 5–>30), lead us to suspect a possible association of NTHL1 mutations with nonpolyposis CRC 
and serrated/hyperplastic polyposis.
Based on previous evidence and with the aim of refining the phenotypic characteristics of the 
NTHL1-associated syndrome, here we evaluated the implication of NTHL1 biallelic mutations in the predisposi-
tion to personal or familial history of multiple tumor types, familial/early-onset nonpolyposis CRC, and serrated/
hyperplastic polyposis.
Materials and Methods
patients. In order to evaluate the role of NTHL1 biallelic mutations in the context of a multi-tumor syndrome, 
we studied 312 unrelated cancer-affected patients who fulfilled the selection criteria indicated in Supplementary 
Table 1 and without mutations in the high penetrance genes associated with the corresponding phenotypes. 
Briefly, we included cancer-affected individuals with personal or familial history of: (i) colorectal, endometrial, 
small intestine or gastric cancer AND breast or ovarian cancer (n = 122); (ii) brain cancer AND any other tumor 
(n = 22); (iii) breast, endometrial, brain or skin cancer AND > 5 adenomatous or hyperplastic polyps (classic and 
attenuated familial adenomatous polyposis excluded) (n = 34); (iv) multiple primary tumors (excluding the com-
binations indicated in the previous categories) (n = 30); and (v) patients fulfilling the clinical criteria for germline 
TP53 mutational screening but with no mutations in the gene (Li-Fraumeni) (n = 104).
A total of 488 hereditary nonpolyposis CRC cases (473 families) were also included in the study5. 
Nonpolyposis cases were mismatch repair (MMR)-proficient, i.e., their tumors showed microsatellite stability 
and expression of the MMR proteins MLH1, MSH2, MSH6, and PMS2. All tested individuals were affected with 
cancer, 96.3% with CRC. The mean age at cancer diagnosis was 49 (range: 16–82). Among the 473 studied fam-
ilies, 58 (12.2%) fulfilled the Amsterdam criteria, 385 (81.4%) the Bethesda guidelines, and 30 (6.3%), none the 
established criteria for hereditary nonpolyposis CRC. Detailed description of the hereditary nonpolyposis CRC 
cases is shown in Supplementary Table 2.
Also, 96 individuals diagnosed with hyperplastic/serrated polyposis9, were screened for germline mutations in 
NTHL1. Description of this cohort is shown in Supplementary Table 3.
All patients were assessed at the Hereditary Cancer Program of the Catalan Institute of Oncology (Spain) 
between 1999 and 2017. Informed consent was obtained from the participants and all methods were performed 
in accordance with relevant guidelines and regulations. The study received the approval of the Ethics Committee 
of the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL).
Mutational screening of NTHL1. NTHL1 c.268C > T (p.Q90*) was genotyped in all patients by using a KASP 
genotyping assay (LGC Genomics, Hoddesdon, UK) in a LightCycler® 480 system (Roche, Basel, Switzerland).
Mutational screening of protein-coding exons and flanking sequences (+/−20 base pairs) was performed by 
direct automated (Sanger) sequencing in the 312 cancer patients with familial/personal history of multiple tumor 
types and in the 96 individuals with hyperplastic/serrated polyposis. Sequencing was performed at STAB VIDA 
(Caparica, Portugal) and data was analyzed with SeqMan Pro (Lasergene 13, DNASTAR, Madison, WI) and/or 
Mutation Surveyor v.3.10 (SoftGenetics, State College, PA). The primers used for amplification and sequencing 
are shown in Supplementary Table 4.
Hereditary nonpolyposis CRC patients were screened for NTHL1 mutations using a combination of PCR 
amplification in pooled DNAs and targeted massively parallel sequencing, as previously described10, using the 
amplification primers listed in Supplementary Table 4. Sanger sequencing of the affected exon was performed to 
identify the mutated individuals among the samples included in the corresponding DNA pool.
In silico predictions. The impact of missense variants at the protein level was analyzed using the in silico 
algorithms PolyPhen-2, SIFT, CONDEL, Mutation Taster and Align GVGD11–15. The potential effects on splicing 
were evaluated by using Human Splice Finder v.3.016. Except for CONDEL, prediction data were provided by 
Alamut Visual v2.7.1 (Interactive Biosoftware, Rouen, France).
pCR amplicon cloning. Exons 2–4 (2,985 bp) were PCR amplified in the gDNA extracted from the car-
rier of NTHL1 c.268C>T and c.550-1G>A, cloned into the pGEM-T Easy Vector System (Promega, Madison, 
Wisconsin, USA) and transformed into JM109 competent cells (Promega). Individual colonies were isolated, PCR 
amplified and sequenced.
NTHL1 constitutional methylation. Methylation of the promoter of NTHL1 was analyzed by means of 
methylation-specific melting curve analysis (MS-MCA) on bisulfite-modified DNA (EZ DNA Methylation-Gold Kit, 
Zymo Research, Orange, CA, USA). Thirty-eight and 17 CpG sites located in the NTHL1 promoter region were evalu-
ated in two independent assays. Methylation status was determined comparing melting curves obtained from samples 
versus controls, which included the CpG methylated Jurkat genomic DNA as methylated control, and DNA amplified 
by whole genome amplification as non-methylated control. Primer sequences are shown in Supplementary Table 4.
NTHL1 copy number alterations. Assessment of copy number variation in the NTHL1 region was carried 
out using the Illumina Infinium Global Screening Array v2.0. Data on hybridization intensity for each probe were 
used to calculate the Log R ratio (LRR) and B allele frequency (BAF) values. These values were used to identify 
copy number regions and to segment the genome. Segmentation calculations were performed with genoCN soft-
ware17 using the R package.
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Results and Discussion
No biallelic NTHL1 mutation carriers were identified among the 312 patients with familial/personal history 
of multiple tumor types (polyposis and patients fulfilling the clinical criteria for hereditary nonpolyposis CRC 
cancer, were excluded). The c.268C>T (p.Q90*) recurrent pathogenic mutation, c.444G>A (p.A148=) and 
c.527 T>C (p.I176T), were identified in heterozygosis in 3 unrelated patients (Supplementary Table 5).
NTHL1 mutational screening in the 488 MMR-proficient hereditary colorectal cancer patients (473 fami-
lies), which included 58 families fulfilling the Amsterdam criteria, identified one compound heterozygous of 
c.268C>T (p.Q90*) and c.550-1G>A (Table 1). No additional relatives were available for segregation analysis. 
Cloning of the PCR product that included the two variants confirmed the biallelic nature of the mutations; i.e., 
they were found to be in different alleles, in trans (Supplementary Fig. 1). In addition to the biallelic mutation 
carrier, one heterozygous carrier of c.268C>T (p.Q90*), one of c.550-1G>A, one of c.793G>A (p.A265T) and 
two of c.527T>C (p.I176T), were identified (Supplementary Table 6). NTHL1 was re-sequenced in the five het-
erozygotes in order to assess the presence of a second mutation, but none was detected. The two carriers of 
c.268C>T (p.Q90*) in the MMR-proficient nonpolyposis CRC series had been previously identified by our group 
by mutation-specific genotyping5. However, in that study, sequencing of the complete coding region of NTHL1 
in the two carriers failed to identify in one of them the herein reported second NTHL1 mutation, c.550-1G>A, 
possibly due to allele dropout.
The biallelic carrier of the NTHL1 pathogenic mutations c.[268C>T]; [550-1G>A] was diagnosed with CRC 
and 3 adenomas at age 37, thus fulfilling the Bethesda criteria for hereditary CRC. Review of her updated clinical 
history revealed that annual/biennial colonoscopy screenings between ages 37–46 (8 colonoscopies) detected 
a total of 26 adenomas and 8 hyperplastic polyps, which now leads to a reclassification as attenuated polyposis. 
Moreover, she was diagnosed with a meningioma at 45 years of age (Family pedigree in Fig. 1).
Broderick et al. analyzed NTHL1 from whole-exome sequencing data performed in 863 unexplained familial/
early-onset CRC cases, finding no biallelic mutations in nonpolyposis CRC patients (biallelic NTHL1 mutations 
were identified in a 41 year-old patient diagnosed with CRC and polyposis)3. Likewise, Zhang et al. sequenced 
the NTHL1 gene in 140 patients diagnosed with CRC before 35 years of age (from an unselected series of >2,300 
Chinese CRC patients), finding no pathogenic mutations in the gene18. The additive evidence gathered in these 
two recent studies and ours (total number of patients studied: 1,491; number of NTHL1 biallelic carriers: 1, 
who has been reclassified as having attenuated adenomatous polyposis) suggests that the contribution of biallelic 
NTHL1 mutations to nonpolyposis CRC is null or, at most, negligible.
NTHL1 variant 
(NM_002528.5) Nature dbSNP HSF 3.0
Population MAF 
(GnomAD) Classification
c.268C>T; p.G90* Stop gain rs150766139 n.a. 0.14% (0.19% Eur) Pathogenic
c.550-1G>A Splice site rs779757251 Altered WT acceptor site 0.0086% (0.009% Eur) Pathogenic
Table 1. NTHL1 variants identified in the studied cohorts in biallelic state. Abbreviations: Eur, European non-
Finnish population; GnomAD, Genome Aggregation Database; HSF 3.0, Human Splicing Finder v.3.0; MAF, 
minor allele frequency; n.a., not available information; WT, wildtype.
Figure 1. Pedigree of the carrier of NTHL1 c.[268C>T];[550-1G>A]. Filled black symbol, cancer affected. 
The black arrow is pointing out the index case. Ages at information gathering or at death, when available, are 
indicated on the top-right corner, and ages at cancer diagnosis, after tumour type. Abbreviations: ca, cancer; 
CRC, colorectal cancer; HP, hyperplastic polyps; mut, NTHL1 biallelic carrier.
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On the other hand, no NTHL1 mutations were identified among the 96 serrated polyposis patients, either in 
homozygosis or heterozygosity. Although our findings need to be validated in larger cohorts, they suggest that biallelic 
NTHL1 mutations are not a major cause of serrated polyposis, in spite of the detection of several hyperplastic pol-
yps (range: 5->30) in 6 out of 34 NTHL1 biallelic mutation carriers reported to date, including the c.[268C>T]; [c.550-
1G>A] carrier identified in the current study, with 26 adenomas and 8 hyperplastic polyps detected before age 50.
In the herein studied cohorts, the frequency of heterozygous missense, splice-site and loss-of-function var-
iants (population minor allele frequency (MAF) < 1%) in NTHL1 (NM_002528.5): 3/312 (0.96%) in patients 
with personal and/or familial history of multiple tumor types, 5/487 (1.03%) (5/472 (1.06%) if only unrelated 
patients are considered) in hereditary nonpolyposis CRC - the NTHL1-mutated attenuated adenomatous poly-
posis patient excluded-, and 0/96 (0%) in hyperplastic/serrated polyposis, is not higher than the frequency identi-
fied in European cancer-free population, i.e. 1.74% (75/4299 individuals; source: NHLBI GO Exome Sequencing 
Project http://evs.gs.washington.edu/EVS/), a priori supporting the lack of association of monoallelic NTHL1 
mutations with cancer predisposition.
Although never reported before, we assessed the presence of NTHL1 promoter hypermethylation in the iden-
tified monoallelic mutation carriers in order to discard the presence of other types of alterations affecting the -a 
priori- wildtype allele. None of the eight heterozygotes showed constitutional NTHL1 CpG island methylation 
(Supplementary Fig. 2). Copy number alteration analysis could be performed in six of the eight monoallelic muta-
tion carriers identified, finding no large deletions or rearrangements affecting the gene. Of note, neither our study 
nor previous analyses reported so far have included the study of large deletions or constitutional epimutations in 
NTHL1 in the complete series, which might have caused the under-detection of mutations in the studied cohorts.
In conclusion, our findings suggest that: (i) the NTHL1-associated syndrome is not a multi-tumor syndrome 
in absence of adenomatous polyposis, (ii) the serrated polyposis syndrome is not caused by NTHL1 mutations, 
and (iii) the presence of biallelic NTHL1 mutation carriers in hereditary CRC patients without polyposis is, if any, 
extremely rare.
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